TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Cervomed Inc.
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

CervoMed presented Phase 2b trial results showing neflamapimod significantly slows clinical progression in dementia with Lewy bodies, with most prominent improvements in patients without AD co-pathology. The company plans to initiate Phase 3 trials in 2026.

Insights
AMD   negative

Experienced stock price decline despite strong results


CRVO   positive

Demonstrated promising clinical trial results with statistically significant improvements in primary and secondary outcome measures, reduced neurodegeneration biomarkers, and plans to advance to Phase 3 trials